10-K - Celularity Inc (0001752828) (Filer)

8-K - Celularity Inc (0001752828) (Filer)

8-K - Celularity Inc (0001752828) (Filer)

NT 10-K - Celularity Inc (0001752828) (Filer)

8-K - Celularity Inc (0001752828) (Filer)

RW - Celularity Inc (0001752828) (Filer)

8-K - Celularity Inc (0001752828) (Filer)

8-K - Celularity Inc (0001752828) (Filer)

EFFECT - Celularity Inc (0001752828) (Filer)

SCHEDULE 13G/A - Celularity Inc (0001752828) (Subject)

FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees required by Listing Rule 5250(f) and accordingly the Company will be delisted unless it appeals this determination. The Company's past due fee balance totaled $70,000. On April 25, 2025, the Company paid in full the fee balance owed to Nasdaq. Additionally, on April 16, 2024, Nasdaq notified the Company that it is delinquent in filing its Form 10-K for the year ended December 31, 2024, and therefore, does not comply with Listing Rule 5250(c)(

FLORHAM PARK, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, welcomes action by the Centers for Medicare & Medicaid Services, or CMS, to revise to January 1, 2026, the effective date of the Medicare Local Coverage Determination, or LCD, titled "Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers" first published in November 2024. An LCD is a determination by a Medicare Administrative Contractor, or MAC, whether to cover a particular service on a MAC-wide, basis. A MAC processes Medicare Part A and Part B claims for a d

FLORHAM PARK, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced a key publication in the April 4, 2025, issue of the prestigious peer-reviewed journal Frontiers in Immunology, the official journal of the International Union of Immunological Societies. In "Senescence, NK cells, and cancer: navigating the crossroads of aging and disease," Celularity scientists discuss how aging may influence the battle between the immune system and cancer, and the implications of senoablative Natural Killer, or NK, cells in disease progression. They emphasize that "preserving the function of N

FLORHAM PARK, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that on December 19, 2024, it received recommendation letters from the US Food and Drug Administration, or FDA, Tissue Reference Group, or TRG, in response to the Company's requests regarding its Natalin and Acelagraft™ products confirming that each product "appears to meet all the criteria for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271." FDA's recommendations reflect that each meets the criteria to be regulated solely under section 361 (21 CRFR Part 1271.10(a)) as a

FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. (BSB) covering manufacturing activities for certain BSB cell therapy products. This collaboration is the second of its kind for Celularity and demonstrates the Company's ability to leverage its world class cGMP manufacturing infrastructure and deep expertise to attract clients like BSB, who are seeking differentiated alternatives to manufacture their therapeutic products in an ever-changing landscape. This collaboration fu

FLORHAM PARK, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Celularity issues the following announcement on behalf of the members of the MASS Coalition: MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDsPresident Trump's Freeze Order Applies to Skin Substitute LCDs – LCDs will not be effective until at least April 13, 2025 The MASS Coalition applauds President Trump for his bold action ordering a freeze of all regulatory guidance not yet in effect, which includes the recent Medicare Local Coverage Determinations restricting access to skin substitute products. The "Freeze Order" specifically encompasses "guidance documents," which include the recent Skin Substitute LCDs. We thank

FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it has received a letter from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq"), confirming that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"). Following the filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2024, Nasdaq has determined that the matter is now closed. "We are pleased to have fully addressed Nasdaq's requirements and resolved this matter, ensuring that our stock remains listed and continues to trade

Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same periods in 2023 FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings. For the nine months

FLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on November 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") stating that the Company does not comply with the Nasdaq continued listing requirements due to the Company's inability to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Q3 Form 10-Q"). Nasdaq's notice has no immediate effect on the listing of Celularity's co

FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel (the "Hearings Panel") has cancelled the previously scheduled hearing regarding Celularity's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), as the Company has cured its filing delinquency. The matter is now closed, and Nasdaq has confirmed that Celularity's stock will continue to be listed and traded on The Nasdaq Stock Market. This resolution follows Nasdaq's prior notification on October 16, 2024, indicating that Celularity was not in compliance with the Ru

Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously

Oppenheimer downgraded Celularity from Outperform to Perform

H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00

Truist downgraded Celularity from Buy to Hold and set a new price target of $10.00

Oppenheimer initiated coverage of Celularity with a rating of Outperform and set a new price target of $9.00

Morgan Stanley initiated coverage of Celularity with a rating of Equal-Weight and set a new price target of $9.00

Truist Securities initiated coverage of Celularity with a rating of Buy and set a new price target of $12.00

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4/A - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director and/or officer of over a dozen public and private companies in the last five years, six of which have reached over one billion dollars in market value. Previously, Mr. Berman worked at Gol

FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need. Throughout his career, Dr. Ling has made significant contributions to regenera

FLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry. He has deep expertise in corporate reputation, global research and development, product launch and promotion, investor relations and public affairs. He will provide senior strategic communications leadership for C

Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancerAppointed Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer and announced the promotion of two senior executives and the formation of a new Executive CommitteePresenting an abstract at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting that supports the scientific rationale of the CYNK-101Strengthened balance sheet using a combination of a $150 million at-the-market (ATM) facility and a $150 million pre-paid advance agreement FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NAS

FLORHAM PARK, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that Adrian Kilcoyne, M.D., M.P.H., M.B.A., has been appointed Executive Vice President, Chief Medical Officer (CMO) and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective today. Dr. Kilcoyne brings over 15 years of clinical experience to Celularity, having previously served in R&D, medical affairs, and commercialization roles, primarily focused on oncology. He has a track record of advancing early-stage clinical programs through commercialization and will p

FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today announced the appointment of Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President effective today. Reporting to Robert J. Hariri, M.D., Ph.D., Chairperson and Chief Executive Officer, Dr. Pecora will provide senior leadership to advance Celularity's clinical pipeline toward U.S. Food and Drug Administration (FDA) approval, including responsibility for preclinical and clinical development and regulatory affairs. "It is with great pleasure that we announce Andrew's appointment as Celularity's P

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

SC 13D/A - Celularity Inc (0001752828) (Subject)

SC 13G/A - Celularity Inc (0001752828) (Subject)

SC 13D/A - Celularity Inc (0001752828) (Subject)

SC 13G/A - Celularity Inc (0001752828) (Subject)

SC 13D/A - Celularity Inc (0001752828) (Subject)

SC 13G/A - Celularity Inc (0001752828) (Subject)

SC 13G - Celularity Inc (0001752828) (Subject)

SC 13G/A - Celularity Inc (0001752828) (Subject)

SC 13G - Celularity Inc (0001752828) (Subject)

SC 13G/A - Celularity Inc (0001752828) (Subject)